SearchDictionaryMobileLogin

Steven A Rosenberg Selected Research

Antigens

06/2008Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
04/2007IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells.
10/2006Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
11/2005Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
05/2005TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.
03/2005CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
11/2004Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
03/2004Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
01/2004Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination.
10/2003Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes.
09/2003High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
08/2003Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
07/2003Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
05/2003Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
05/2003Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.
05/2003Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.
02/2003Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
01/2003CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens.
09/2002Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
06/2002The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy.
05/2002A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
03/2002Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy.
01/2002Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy.
01/2002Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction.

Articles by Research Topic

Disease

34Neoplasms (Cancer)
09/2008 - 03/2002
27Melanoma (Melanoma, Malignant)
09/2008 - 01/2002
3Kidney Neoplasms (Kidney Cancer)
09/2007 - 07/2003
1Enteritis
11/2007
1Enterocolitis
05/2006
1Uveitis
11/2004
1Renal Cell Carcinoma (Grawitz Tumor)
07/2004
1Colorectal Neoplasms (Colorectal Cancer)
10/2003
1Hypercalcemia (Milk Alkali Syndrome)
02/2003
1Waardenburg's Syndrome (Waardenburg Syndrome)
06/2002
1Neoplasm Metastasis (Metastasis)
01/2002

Drug/Important Bio-Agent (IBA)

24AntigensIBA
06/2008 - 01/2002
11Interleukin-2 (IL2)IBA
09/2008 - 01/2002
6cytotoxic T-lymphocyte antigen 4IBA
07/2008 - 07/2003
3VaccinesIBA
09/2008 - 09/2004
2Interleukin-15 (Interleukin 15)IBA
04/2007 - 02/2004
2EpitopesIBA
11/2004 - 03/2004
2bevacizumabFDA Link
07/2004 - 07/2003
2PeptidesIBA
07/2003 - 05/2003
1ipilimumabIBA
11/2007
1Immunotoxins (Immunotoxin)IBA
10/2007
1B3(Fv)-PE38KDEL recombinant immunotoxinIBA
10/2007
1Toll-Like Receptors (Toll-Like Receptor)IBA
09/2007
1Monophenol Monooxygenase (Tyrosinase)IBA
04/2006
1Diphtheria ToxinIBA
11/2005
1denileukin diftitox (Ontak)FDA Link
11/2005
1Transforming Growth Factor beta1 (TGF beta 1)IBA
05/2005
1HLA-A*0201 antigenIBA
11/2004
1Telomerase (Telomerase Reverse Transcriptase)IBA
07/2004
1Thalidomide (Thalomid)FDA Link
07/2004
1Glycoproteins (Glycoprotein)IBA
09/2003
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2003
1DNA (Deoxyribonucleic Acid)IBA
05/2003
1Immunodominant EpitopesIBA
05/2003
1Parathyroid Hormone-Related ProteinIBA
02/2003
1Differentiation AntigensIBA
11/2002
1flt3 ligand protein (flt3 ligand)IBA
05/2002
1Interferon-alpha (Interferon Alfa)FDA Link
03/2002
1tyrosinase-related proteinIBA
01/2002

Therapy/Procedure

13Immunotherapy
09/2008 - 01/2002
2Drug Therapy (Chemotherapy)
04/2005 - 05/2002
1Tissue Therapy (Cell Therapy)
05/2008
1Therapeutics
05/2003